Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giles Best

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Leukemia & Lymphoma|January 16, 2024
The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells <i>in vitro</i>Narjis Fatima, Yandong Shen, Kyle Crassini, et al.
British Journal of Haematology|February 23, 2018
Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic LeukaemiaKyle R Crassini, Eva Zhang, Shalini Balendran, et al.
ACS Biomaterials Science & Engineering|June 25, 2025
Deciphering the Role of Biomaterial Surface Chemistry in Toll-Like Receptor-Mediated Immune ModulationMarkos Negash Alemie, Richard Bright, Neethu Ninan, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|November 14, 2009
Inhibition of protein kinase CK2 closes the CFTR Cl channel, but has no effect on the cystic fibrosis mutant deltaF508-CFTRKate J Treharne, Zhe Xu, Jeng-Haur Chen, et al.
Ejhaem|July 18, 2022
Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndromeYandong Shen, Luke Coyle, Ian Kerridge, et al.
The Journal of Biological Chemistry|February 10, 2007
Protein kinase CK2, cystic fibrosis transmembrane conductance regulator, and the deltaF508 mutation: F508 deletion disrupts a kinase-binding siteKate J Treharne, Russell M Crawford, Zhe Xu, et al.
Kidney360|August 14, 2025
Novel Molecular Signatures of Peripheral Regulatory T Cells in Kidney Disease Associated With Type 1 DiabetesAmita Bansal, Soon Wei Wong, Wilson K M Wong, et al.
Leukemia Research|November 25, 2010
CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLLAneela Majid, Thet Thet Lin, Giles Best, et al.
Cancers|January 11, 2025
A Novel In Vitro Model of the Bone Marrow Microenvironment in Acute Myeloid Leukemia Identifies CD44 and Focal Adhesion Kinase as Therapeutic Targets to Reverse Cell Adhesion-Mediated Drug ResistanceEleni E Ladikou, Kim Sharp, Fabio A Simoes, et al.
Cell Death & Disease|June 2, 2026
USP2 is an androgen-repressed survival factor that stabilises oncoproteins to facilitate therapy resistance in prostate cancerDanielle Meiwen Fang, Raj K Shrestha, Beatriz German, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Leukemia & Lymphoma|January 16, 2024
The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells <i>in vitro</i>Narjis Fatima, Yandong Shen, Kyle Crassini, et al.
British Journal of Haematology|February 23, 2018
Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic LeukaemiaKyle R Crassini, Eva Zhang, Shalini Balendran, et al.
ACS Biomaterials Science & Engineering|June 25, 2025
Deciphering the Role of Biomaterial Surface Chemistry in Toll-Like Receptor-Mediated Immune ModulationMarkos Negash Alemie, Richard Bright, Neethu Ninan, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|November 14, 2009
Inhibition of protein kinase CK2 closes the CFTR Cl channel, but has no effect on the cystic fibrosis mutant deltaF508-CFTRKate J Treharne, Zhe Xu, Jeng-Haur Chen, et al.
Ejhaem|July 18, 2022
Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndromeYandong Shen, Luke Coyle, Ian Kerridge, et al.
The Journal of Biological Chemistry|February 10, 2007
Protein kinase CK2, cystic fibrosis transmembrane conductance regulator, and the deltaF508 mutation: F508 deletion disrupts a kinase-binding siteKate J Treharne, Russell M Crawford, Zhe Xu, et al.
Kidney360|August 14, 2025
Novel Molecular Signatures of Peripheral Regulatory T Cells in Kidney Disease Associated With Type 1 DiabetesAmita Bansal, Soon Wei Wong, Wilson K M Wong, et al.
Leukemia Research|November 25, 2010
CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLLAneela Majid, Thet Thet Lin, Giles Best, et al.
Cancers|January 11, 2025
A Novel In Vitro Model of the Bone Marrow Microenvironment in Acute Myeloid Leukemia Identifies CD44 and Focal Adhesion Kinase as Therapeutic Targets to Reverse Cell Adhesion-Mediated Drug ResistanceEleni E Ladikou, Kim Sharp, Fabio A Simoes, et al.
Cell Death & Disease|June 2, 2026
USP2 is an androgen-repressed survival factor that stabilises oncoproteins to facilitate therapy resistance in prostate cancerDanielle Meiwen Fang, Raj K Shrestha, Beatriz German, et al.
Pageof 7